“This is principally a huge engineering exercise that has proven feasible, that individual cells can be taken from the blood of a patient with a solid tumor, identified in small numbers in such a condition we now can look at the molecular profile of an individual cancer. That’s a huge advance.”
Scientists at Massachusetts General Hospital in Boston invented the new blood test. Logothetis says there will be a few years of clinical trials, and MD Anderson will take part. Doctors could later use this test, or something similar, to pinpoint chemotherapy more exactly according to what kinds of cancer cells are circulating in a patient’s blood. The theory is that they can dial up the dosage of one drug, or dial back another, according to the blood test.
“It could prolong life, reduce the side effects of unnecessary therapies and has the potential to increase the efficiency of drug development, reducing the overall cost dramatically.”
Logothetis says other companies are working on their own blood tests, and it’s unclear which technology will emerge the winner, and at what price. From the KUHF Health Science and Technology Desk, I’m Carrie Feibel.